Low bone mineral density among HIV-infected patients in Brazil

Carregando...
Imagem de Miniatura
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEDICINA TROPICAL SAO PAULO
Citação
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.59, article ID UNSP e89, 5p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Decrease in bone mineral density (BMD) has been a complication among people living with HIV/AIDS. To investigate the prevalence of osteopenia/osteoporosis among HIV-infected people living in Sao Paulo city, we studied 108 HIV-infected patients (79 men and 29 women). We extracted data from patients' medical records and BMD was measured by dual-energy X-ray absorptiometry (DXA). Median age of participants was 42 years (interquartile range [IQR] 36-48 years), and the median time since HIV diagnosis was 4.01 years (IQR 2-11 years). Patients had acquired HIV primarily by the sexual route (men who have sex with men 44%, heterosexual 49%). Median age, duration of HIV infection, duration of ART and CD4 nadir were similar for men and women. Plasma viral load was undetectable for 53 patients (49%). Median CD4 T cell count was 399 cells/mu L (IQR 247 - 568). Twenty five patients (23%) had LBMD, and there was no statistically significant difference between men and women (<-1). The associated risk factors for LBMD were older age (>= 50 years old) and smoking with a RR of 3.87 and 2.80, respectively. Thus, despite the lack of statistically significant relationship between the use of ART and LBMD or between duration of ART and LBMD, these factors should be addressed in larger studies.
Palavras-chave
HIV, Bone mineral, Osteoporosis, Risk factors
Referências
  1. Alcalde R, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-156
  2. Araújo Denizar Vianna, 2005, Arq Bras Endocrinol Metab, V49, P897, DOI 10.1590/S0004-27302005000600007
  3. Baim S, 2008, J CLIN DENSITOM, V11, P75, DOI 10.1016/j.jocd.2007.12.007
  4. Bonjoch A, 2010, AIDS, V24, P2827, DOI 10.1097/QAD.0b013e328340a28d
  5. Bortolon PC, 2011, CAD SAUDE PUBLICA, V27, P733, DOI 10.1590/S0102-311X2011000400012
  6. Bow CH, 2011, OSTEOPOROSIS INT, V22, P2799, DOI 10.1007/s00198-010-1490-0
  7. Brown TT, 2007, AIDS, V21, P1830, DOI 10.1097/QAD.0b013e3282703837
  8. Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
  9. Casseb J, 2012, REV INST MED TROP SP, V54, P257, DOI 10.1590/S0036-46652012000500004
  10. Cazanave C, 2008, AIDS, V22, P395, DOI 10.1097/QAD.0b013e3282f423dd
  11. Chitu-Tisu C. E., 2016, GERMS, V6, P50
  12. Cotter AG, 2014, AIDS, V28, P2051, DOI 10.1097/QAD.0000000000000353
  13. Eleftheriou KI, 2013, BONE, V52, P17, DOI 10.1016/j.bone.2012.09.003
  14. Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
  15. Jones S, 2008, OSTEOPOROSIS INT, V19, P913, DOI 10.1007/s00198-007-0524-8
  16. Langkilde A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051698
  17. Malta M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1530-y
  18. Nunn AS, 2007, PLOS MED, V4, P1804, DOI 10.1371/journal.pmed.0040305
  19. Neto LFSP, 2011, J CLIN DENSITOM, V14, P434, DOI 10.1016/j.jocd.2011.06.004
  20. Sales SH, 2015, SCI REP-UK, V5, DOI 10.1038/srep12990
  21. Schafer JJ, 2013, PHARMACOTHERAPY, V33, P665, DOI 10.1002/phar.1257
  22. Soares LR, 2015, REV INST MED TROP SP, V57, P105, DOI 10.1590/S0036-46652015000200002
  23. Yin M, 2005, OSTEOPOROSIS INT, V16, P1345, DOI 10.1007/s00198-005-1845-0
  24. Yong MK, 2011, JAIDS-J ACQ IMM DEF, V57, P205, DOI 10.1097/QAI.0b013e31821ecf4c
  25. Young B, 2011, CLIN INFECT DIS, V52, P1061, DOI 10.1093/cid/ciq242
  26. Zhang N, 2016, BIOSCI TRENDS, V10, P277, DOI 10.5582/bst.2016.01081